KY-226 is a potent, selective, orally active and allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC 50 of 0.25 μM, and without PPARγ agonist activity. KY-226 exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively. KY-226 also protects neurons from cerebral ischemic injury.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Obesity | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Phosphatase
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.